Unraveling the Mystery of Prognostic and Predictive Factors in Epidermal Growth Factor Receptor Therapy
- 1 March 2006
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (7) , 1219-1220
- https://doi.org/10.1200/jco.2005.04.4420
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- EGFR and erbB2 mutation status in Japanese lung cancer patientsInternational Journal of Cancer, 2005
- Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group StudyJournal of Clinical Oncology, 2005
- Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2005
- Selecting Patients for Epidermal Growth Factor Receptor Inhibitor Treatment: A FISH Story or a Tale of Mutations?Journal of Clinical Oncology, 2005
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005
- Individual benefits from adjuvant anthracycline-based chemotherapy can be predicted from a predictive nomogram created from primary chemotherapy (PC) data: Results of a randomized trialJournal of Clinical Oncology, 2005
- Radiation Therapy and Tamoxifen: Concurrent or Sequential? That Is the QuestionJournal of Clinical Oncology, 2005